Literature DB >> 15858001

The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice.

Weiping Peng1, Gail Henderson, Melissa Inman, Lbachir BenMohamed, Guey-Chuen Perng, Steven L Wechsler, Clinton Jones.   

Abstract

The herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) is the only abundant viral transcript expressed in latently infected neurons. LAT inhibits apoptosis, suggesting that it regulates latency by promoting the survival of infected neurons. The LAT locus also contains a newly described gene (AL), which is antisense to LAT and partially overlaps LAT encoding sequences. When human (SK-N-SH) or mouse (neuro-2A) neuroblastoma cells were infected with a virus that does not express LAT or AL gene products (dLAT2903), beta interferon (IFN-beta) and IFN-alpha RNA expression was detected earlier relative to the same cells infected with HSV-1 strains that express LAT and AL. Infection of neuro-2A cells with dLAT2903 also led to higher levels of IFN-beta promoter activity than in cells infected with wild-type (wt) HSV-1. In contrast, IFN RNA expression was the same when human lung fibroblasts were infected with dLAT2903 or wt HSV-1. When BALB/c mice were infected with dLAT2903, IFN-alpha and IFN-beta RNA expression was readily detected in trigeminal ganglia (TG) 4 days after infection. These transcripts were not detected in TG of mice infected with wt HSV-1 or dLAT2903R (marker-rescued dLAT2903) until 6 days postinfection. When TG single-cell suspensions from infected BALB/c mice were prepared and incubated in vitro with wt HSV-1 as a source of antigen, TG cultures prepared from mice infected with dLAT2903 produced and secreted higher levels of IFN protein than wt HSV-1 or dLAT2903R. Collectively, these studies suggest that the LAT locus interferes with and delays IFN expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858001      PMCID: PMC1091686          DOI: 10.1128/JVI.79.10.6162-6171.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo.

Authors:  Maryam Ahmed; Martin Lock; Cathie G Miller; Nigel W Fraser
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 2.  Herpes simplex encephalitis.

Authors:  B Sköldenberg
Journal:  Scand J Infect Dis Suppl       Date:  1991

3.  A protein encoded by the herpes simplex virus (HSV) type 1 2-kilobase latency-associated transcript is phosphorylated, localized to the nucleus, and overcomes the repression of expression from exogenous promoters when inserted into the quiescent HSV genome.

Authors:  S K Thomas; C E Lilley; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Analysis of bovine trigeminal ganglia following infection with bovine herpesvirus 1.

Authors:  M T C Winkler; A Doster; J H Sur; C Jones
Journal:  Vet Microbiol       Date:  2002-04-22       Impact factor: 3.293

5.  Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA.

Authors:  T V Sharp; M Schwemmle; I Jeffrey; K Laing; H Mellor; C G Proud; K Hilse; M J Clemens
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

6.  Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.

Authors:  Asuka Nanbo; Kaori Inoue; Kumi Adachi-Takasawa; Kenzo Takada
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

7.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection.

Authors:  T Liu; Q Tang; R L Hendricks
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.

Authors:  K Megyeri; W C Au; I Rosztoczy; N B Raj; R L Miller; M A Tomai; P M Pitha
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

10.  Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency.

Authors:  N M Sawtell; R L Thompson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  33 in total

Review 1.  Herpes simplex virus type 1 persists in the aged brain through hypothetical expression of accessory genes.

Authors:  Isamu Mori
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Virus and cell RNAs expressed during Epstein-Barr virus replication.

Authors:  Jing Yuan; Ellen Cahir-McFarland; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  A herpes simplex virus type 1 mutant disrupted for microRNA H2 with increased neurovirulence and rate of reactivation.

Authors:  Xianzhi Jiang; Don Brown; Nelson Osorio; Chinhui Hsiang; Lily Li; Lucas Chan; Lbachir BenMohamed; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-02-03       Impact factor: 2.643

4.  Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.

Authors:  Lbachir BenMohamed; Nelson Osorio; Ruchi Srivastava; Arif A Khan; Jennifer L Simpson; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

5.  Identification of herpes simplex virus type 1 proteins encoded within the first 1.5 kb of the latency-associated transcript.

Authors:  Gail Henderson; Tareq Jaber; Dale Carpenter; Steven L Wechsler; Clinton Jones
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

6.  Increased neurovirulence and reactivation of the herpes simplex virus type 1 latency-associated transcript (LAT)-negative mutant dLAT2903 with a disrupted LAT miR-H2.

Authors:  Xianzhi Jiang; Don Brown; Nelson Osorio; Chinhui Hsiang; Lbachir BenMohamed; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-06-12       Impact factor: 2.643

7.  The herpes simplex virus type 1 locus that encodes the latency-associated transcript enhances the frequency of encephalitis in male BALB/c mice.

Authors:  Clinton Jones; Melissa Inman; Weiping Peng; Gail Henderson; Alan Doster; Guey-Chuen Perng; Anisa Kaenjak Angeletti
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.

Authors:  Anthony B Nesburn; Ilham Bettahi; Gargi Dasgupta; Alami Aziz Chentoufi; Xiuli Zhang; Sylvaine You; Naoyuki Morishige; Andrew J Wahlert; Donald J Brown; James V Jester; Steven L Wechsler; Lbachir BenMohamed
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  Investigation of the mechanism by which herpes simplex virus type 1 LAT sequences modulate preferential establishment of latent infection in mouse trigeminal ganglia.

Authors:  Yumi Imai; Kathleen Apakupakul; Philip R Krause; William P Halford; Todd P Margolis
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  Identification of a novel herpes simplex virus type 1 transcript and protein (AL3) expressed during latency.

Authors:  Tareq Jaber; Gail Henderson; Sumin Li; Guey-Chuen Perng; Dale Carpenter; Steven L Wechsler; Clinton Jones
Journal:  J Gen Virol       Date:  2009-07-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.